Dengue Fever And Vaccine Information Center

Dengue fever is a destructive mosquito-borne flavivirus with about half of the world’s population at risk. There are roughly 390 million infections globally per year. A dengue vaccine is considered to be an excellent solution to prevent and protect people at risk from the virus.  The first licensed dengue vaccine is Dengvaxia (CYD-TDV). It is a live attenuated tetravalent chimeric vaccine made using recombinant DNA innovation. It is given in three different dosages with six months intervals. WHO Strategic Advisory Group of Experts (SAGE) on Immunisation recommended that Dengvaxia should